Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ELAGOLIX vs GANIRELIX ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.
Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Management of moderate to severe pain associated with endometriosis
Inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology (ART),Off-label: Treatment of hormone-sensitive cancers (e.g., prostate cancer) when rapid suppression of gonadotropins is needed
200 mg orally twice daily
250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.
Terminal elimination half-life is approximately 4–6 hours. Clinical context: Steady state achieved within 5 days; tid dosing maintains therapeutic concentrations.
Terminal elimination half-life is approximately 16.2 hours (range 11-19 hours) in healthy females; clinically supports once-daily dosing.
Primarily metabolized by CYP3A4; minor contribution from CYP2D6 and CYP2C8.
Primarily hepatically metabolized via peptide hydrolysis; no major CYP450 involvement.
Renal (approximately 70% as unchanged drug and metabolites), fecal (approximately 30%)
Renal (approximately 75% as unchanged drug and metabolites) and fecal (approximately 22%).
Approximately 99% bound to albumin and alpha-1-acid glycoprotein
Approximately 90%, primarily to albumin and alpha-1-acid glycoprotein.
Vd/F is approximately 40–60 L (0.5–0.8 L/kg). Clinical meaning: Extensive tissue distribution, consistent with a large volume of distribution.
Approximately 0.9 L/kg, indicating distribution primarily into extracellular fluid and some tissue binding.
Oral: Approximately 30% (low due to first-pass metabolism); food increases exposure by approximately 30%.
Subcutaneous: Approximately 100% (range 91-100%) relative to intravenous injection.
e GFR 30-89 m L/min: no adjustment. e GFR 15-29 m L/min: 100 mg twice daily. e GFR <15 m L/min: not recommended.
No dose adjustment required for mild to moderate renal impairment. No data for severe renal impairment (Cr Cl < 30 m L/min).
Child-Pugh A: no adjustment. Child-Pugh B: 100 mg twice daily. Child-Pugh C: not recommended.
No clinical data for hepatic impairment. Use with caution in moderate to severe hepatic impairment.
Not established; safety and efficacy in pediatric patients have not been studied.
Not approved for use in pediatric patients.
No specific dose adjustment required; clinical studies included limited patients ≥65 years, but no differences in safety or efficacy observed.
Not approved for use in geriatric patients.
None
None
Hepatic transaminase elevations: monitor liver function before and during treatment; discontinue if elevation >3x ULN or if signs of liver injury occur.,Bone density loss: monitor bone mineral density with long-term use; consider additional calcium/vitamin D.,Mood changes: increased risk of depression, suicidal ideation; monitor for new or worsening symptoms.,Altered menstrual bleeding; exclude pregnancy before starting.,Risk of osteoporosis with prolonged use.
Hypersensitivity reactions (urticaria, angioedema) have been reported,Ovarian hyperstimulation syndrome (OHSS) may occur with ART,Congenital abnormalities cannot be excluded; pregnancy should be excluded before use
Known hypersensitivity to elagolix or any excipients,Concomitant use with strong organic anion-transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine, gemfibrozil),Pregnancy, or women of reproductive potential not using effective contraception,Existing osteoporosis or severe bone loss,History of suicidal ideation or behavior
Hypersensitivity to ganirelix or any component,Known or suspected pregnancy,Lactation (not recommended due to potential neonatal effects)
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase elagolix levels. No other food restrictions.
No significant food interactions. Grapefruit may theoretically affect metabolism but data are lacking; caution is advised.
First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for harm. Elagolix is contraindicated in pregnancy.
Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) due to hormonal disruption.
Elagolix is excreted in animal milk; no human data. M/P ratio unknown. Not recommended during breastfeeding.
Unknown if excreted in human breast milk; M/P ratio not available. Risk of adverse effects in infant due to potential hormonal activity. Use caution; avoid if possible.
No dose adjustments studied; contraindicated in pregnancy. No data on PK changes requiring dose modification.
No dose adjustments in pregnancy; contraindicated. If inadvertently used, discontinue immediately; no study on pharmacokinetic changes in pregnancy.
Elagolix is an oral Gn RH antagonist for endometriosis-associated pain. Monitor bone mineral density (BMD) with dual-energy X-ray absorptiometry (DXA) if using >12 months or in patients with osteoporosis risk. Avoid use with strong CYP3A inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole). May reduce efficacy of hormonal contraceptives. Assess pregnancy status before starting due to teratogenicity.
Administer subcutaneously in the abdomen. Rotate injection sites to prevent lipodystrophy. Monitor for ovarian hyperstimulation syndrome (OHSS) especially in patients with polycystic ovary syndrome. Use caution in patients with renal impairment.
Take elagolix at the same time daily with or without food.,Avoid grapefruit or grapefruit juice during treatment.,Use non-hormonal contraception (e.g., condoms) because elagolix may reduce hormonal contraceptive effectiveness.,Report severe headaches, vision changes, or heavy bleeding promptly.,Do not take elagolix if pregnant or planning to become pregnant; use effective birth control.
Inject exactly as prescribed, typically once daily during the stimulation phase.,Do not skip doses; missed doses may reduce effectiveness.,Report severe pelvic pain, nausea, vomiting, or rapid weight gain immediately.,Store at room temperature (20-25°C) and protect from light.,Use within 30 days after first use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ELAGOLIX vs GANIRELIX ACETATE, answered by our medical review team.
ELAGOLIX is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist that competitively binds to Gn RH receptors in the anterior pituitary, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, thereby suppressing ovarian estradiol production.. GANIRELIX ACETATE is a Gonadotropin-Releasing Hormone Antagonist that works by Gonadotropin-releasing hormone (Gn RH) antagonist competitively blocks Gn RH receptors on pituitary gonadotropes, reducing secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ELAGOLIX and GANIRELIX ACETATE depend on the specific clinical indication. These are both Gonadotropin-Releasing Hormone Antagonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ELAGOLIX is: 200 mg orally twice daily. The standard adult dose of GANIRELIX ACETATE is: 250 mcg subcutaneously once daily starting on day 2 or 3 of menstrual cycle, continued until day of h CG administration.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ELAGOLIX and GANIRELIX ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ELAGOLIX is classified as Category C. First trimester: High risk of pregnancy loss and major birth defects based on animal data and mechanism of action. Second and third trimesters: Contraindicated due to potential for. GANIRELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. Animal studies show embryolethality and teratogenicity. Risk of fetal loss (first trimester) and potential malformations (all trimesters) . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.